I. Niculescu-Duvaz

发表

Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.

Richard D. Taylor, Esteban Roman, Steven Whittaker, 2009, Journal of medicinal chemistry.

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.

S. Whittaker, C. Springer, R. Marais, 2008, Journal of medicinal chemistry.

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

David M. Wilson, S. Whittaker, Arnaud Nourry, 2010, Bioorganic & medicinal chemistry.

Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.

J. Heyes, I. Niculescu-Duvaz, R. Cooper, 1999, Current opinion in molecular therapeutics.

Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy)

I. Niculescu-Duvaz, 1996 .

Section Review: Biologicals & Immunologicals: Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy)

I. Niculescu-Duvaz, C. Springer, 1996 .

Suicide Gene Therapy

C. Springer, I. Niculescu-Duvaz, 2003 .

Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.

C. Springer, R. Marais, I. Niculescu-Duvaz, 2002, Cancer research.

Introduction to the background, principles, and state of the art in suicide gene therapy

C. Springer, I. Niculescu-Duvaz, Caroline J. Springer, 2005, Molecular biotechnology.

Gene therapy for high-grade glioma

J. Yoshida, C. Springer, I. Niculescu-Duvaz, 2008, Cell adhesion & migration.

A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate

C. Springer, I. Niculescu-Duvaz, D. Niculescu-Duvaz, 2005 .

ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

C. Springer, D. Blakey, S. Sharma, 1996, Cancer research.

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

C. Springer, D. Blakey, I. Niculescu-Duvaz, 1995, Journal of medicinal chemistry.

Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody‐Directed Enzyme Prodrug Therapy (ADEPT).

C. Springer, D. Blakey, I. Niculescu-Duvaz, 1996 .

Potential anticancer agents. XX. 2. Quantitative structure--activity relationships (QSAR) in aromatic nitrogen mustards area.

Z. Simon, I. Niculescu-Duvaz, G. Stihi, 1980, Neoplasma.

Potential anticancer agents. XX. 1. Steric fit analysis in aromatic nitrogen mustards area.

Z. Simon, I. Niculescu-Duvaz, T. Crăescu, 1980, Neoplasma.

Approaches to gene-directed enzyme prodrug therapy (GDEPT).

C. Springer, I. Niculescu-Duvaz, 2000, Advances in experimental medicine and biology.

Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations.

I. Niculescu-Duvaz, C. Springer, 1997, Expert opinion on investigational drugs.

Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.

I. Niculescu-Duvaz, R. Pedley, C. Springer, 1994, Journal of medicinal chemistry.

Gene-directed enzyme prodrug therapy.

C. Springer, R. Marais, I. Niculescu-Duvaz, 1998, Bioconjugate chemistry.

Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.

I. Niculescu-Duvaz, 2010, Current opinion in molecular therapeutics.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

S. Heidorn, L. Packer, B. Druker, 2011, Cancer cell.

Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).

C. Springer, I. Niculescu-Duvaz, D. Niculescu-Duvaz, 1999, Anti-cancer drug design.

Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.

I. Niculescu-Duvaz, C. Springer, 1995, Anti-cancer drug design.

Technology evaluation: gemtuzumab ozogamicin, Celltech Group.

I. Niculescu-Duvaz, 2000, Current opinion in molecular therapeutics.

Self-immolative anthracycline prodrugs for suicide gene therapy.

C. Springer, R. Marais, I. Niculescu-Duvaz, 1999, Journal of medicinal chemistry.

Potential anticancer agents. XXVI. Spin Labelled Nitrosoureas

I. Niculescu-Duvaz, V. Dobre, I. Baracu, 1985 .

Potential anticancer agents. 10. Synthesis of N-(4((2,4-diamino-7-pteridyl)methyl)-N10-methylamino)benzoyl)glutamic acid.

I. Niculescu-Duvaz, V. Dobre, R. Bick, 1974, Journal of medicinal chemistry.

Self-immolative nitrogen mustard prodrugs for suicide gene therapy.

C. Springer, R. Marais, I. Niculescu-Duvaz, 1998, Journal of medicinal chemistry.

The emerging fields of suicide gene therapy and virotherapy.

C. Springer, D. Kirn, I. Niculescu-Duvaz, 2002, Trends in molecular medicine.

Potential anticancer agents. IV. Nitrogen mustards of methylbenzoic acids.

I. Niculescu-Duvaz, A. Cambanis, V. Feyns, 1968, Journal of medicinal chemistry.

Potential anticancer agents. V. New aromatic nitrogen mustards related to 3-[N,N-bis(2-chloroethyl)amino]-4-methylbenzoic acid.

I. Niculescu-Duvaz, V. Dobre, A. Cambanis, 1969, Journal of medicinal chemistry.

Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy

I. Niculescu-Duvaz, C. Springer, 1995, Current Medicinal Chemistry.

Directed Enzyme Prodrug Therapies

C. Springer, I. Niculescu-Duvaz, D. Niculescu-Duvaz, 2011 .

Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses.

R. Huddart, I. Niculescu-Duvaz, J. Shipley, 2001, Cancer genetics and cytogenetics.

Prodrug-activating systems in suicide gene therapy.

C. Springer, I. Niculescu-Duvaz, 2000, The Journal of clinical investigation.

CHAPTER 8 – GENE-DIRECTED ENZYME PRODRUG THERAPY

C. Springer, I. Niculescu-Duvaz, 2002 .

Potential anticancer agents. XIX. New Urethanic Type Nitrogen Mustards Derived from Steroidic Structures

I. Niculescu-Duvaz, I. Elian, M. Ionescu, 1979 .

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

S. Whittaker, C. Springer, R. Marais, 2013, Bioorganic & medicinal chemistry.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.

S. Whittaker, Arnaud Nourry, C. Springer, 2010, Journal of medicinal chemistry.

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

Richard D. Taylor, H. Dijkstra, S. Whittaker, 2009, Journal of medicinal chemistry.

Design of prodrugs for suicide gene therapy.

C. Springer, I. Niculescu-Duvaz, D. Niculescu-Duvaz, 2004, Methods in molecular medicine.

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

J. Larkin, M. Gore, C. Fisher, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

P. Wesseling, C. Springer, R. Marais, 2013, Cancer discovery.

BRAF as a therapeutic target: a patent review (2006 – 2012)

C. Springer, R. Marais, I. Niculescu-Duvaz, 2013, Expert opinion on therapeutic patents.

Small molecule inhibitors of BRAF in clinical trials.

C. Springer, R. Marais, I. Niculescu-Duvaz, 2012, Bioorganic & medicinal chemistry letters.

Potential anticancer agents. 16. Methotrexate analogues with a modified peptide side chain.

I. Niculescu-Duvaz, V. Dobre, D. Ionescu, 1978, Journal of medicinal chemistry.

Potential anticancer agents. 17. Analogues of methotrexate with a tripeptide side chain.

I. Niculescu-Duvaz, V. Dobre, G. Botez, 1978, Journal of medicinal chemistry.

Technology evaluation: EMD-273063, EMD Lexigen.

I. Niculescu-Duvaz, 2004, Current opinion in molecular therapeutics.

Potential anticancer agents. XXVIII. Synthesis of Some Cyclohexanone Derived N‐Nitrosoureas

I. Niculescu-Duvaz, I. Baracu, 1985 .

BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.

H. Dijkstra, S. Whittaker, Arnaud Nourry, 2010, Journal of medicinal chemistry.

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.

S. Whittaker, C. Springer, R. Marais, 2006, Journal of medicinal chemistry.

Glufosfamide (Baxter Oncology).

I. Niculescu-Duvaz, 2002, Current opinion in investigational drugs.

Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.

H. Dijkstra, S. Whittaker, Arnaud Nourry, 2010, Journal of medicinal chemistry.

Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs

C. Springer, I. Niculescu-Duvaz, 1996 .

Novel Prodrugs of Alkylating Agents Derived from 2‐Fluoro‐ and 3‐ Fluorobenzoic Acids for Antibody‐Directed Enzyme Prodrug Therapy.

I. Niculescu-Duvaz, R. Pedley, C. Springer, 1994 .

Patent property of suicide gene therapy involving prodrugs 1996 - 1999

C. Springer, I. Niculescu-Duvaz, 1999 .

Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.

C. Springer, R. Marais, I. Niculescu-Duvaz, 2004, Journal of medicinal chemistry.

Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.

C. Springer, R. Marais, I. Niculescu-Duvaz, 2003, Journal of medicinal chemistry.

Antibody-directed enzyme prodrug therapy (ADEPT): a review.

C. Springer, I. Niculescu-Duvaz, Springer, 1997, Advanced drug delivery reviews.

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

David M. Wilson, S. Whittaker, Arnaud Nourry, 2010, Bioorganic & Medicinal Chemistry.

Preparation of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for treating cancer

C. Springer, R. Marais, I. Niculescu-Duvaz, 2013 .

Carcinogenesis Inhibitory Properties of Retinoids: A QSAR-MTD Analysis

Z. Simon, I. Niculescu-Duvaz, N. Voiculetz, 2018 .

Suicide Gene Therapy

C. Springer, I. Niculescu-Duvaz, 2003 .